E

Elanco Animal Health
D

ELAN

8.55000
USD
-0.82
(-8.75%)
Post Trading
Volume
244,520
EPS
1
Div Yield
-
P/E
13
Market Cap
4,244,719,183
Related Instruments
ABBV
ABBV
-5.850
(-3.26%)
173.600 USD
AMGN
AMGN
-9.33
(-3.21%)
281.42 USD
A
AUPH
-0.24000
(-3.16%)
7.36000 USD
BIIB
BIIB
-5.880
(-4.88%)
114.520 USD
BMY
BMY
-3.360
(-6.26%)
50.330 USD
CAH
CAH
-1.430
(-1.10%)
129.010 USD
GILD
GILD
-2.845
(-2.71%)
102.240 USD
I
INO
0.04500
(2.92%)
1.58500 USD
More
News

Title: Elanco Animal Health

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal productsused in cattle, sheep, goats, and swine production.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.